Silk Road Medical, Inc.

Silk Road Medical, Inc. is a medical device company based in Sunnyvale, California. Founded in 2007, the company focuses on reducing stroke risk in patients with carotid artery disease through its innovative transcarotid artery revascularization (TCAR) platform. The TCAR procedure, which received FDA approval in 2015, offers a minimally invasive alternative to traditional open surgery, supported by clinical studies that demonstrate reduced stroke and complication risks. The company provides a range of specialized devices for the TCAR procedure, including the ENROUTE Transcarotid Neuroprotection System, ENROUTE Transcarotid Stent System, ENHANCE Transcarotid Peripheral Access Kit, ENROUTE 0.014 Guidewire, and ENROUTE Enflate Transcarotid RX Balloon Dilation Catheter. These products represent the only commercially available system for TCAR, marking a significant advancement in vascular medicine. Silk Road Medical operates primarily in the United States and anticipates net revenue of $194-198 million in 2024, reflecting steady growth. As of September 2024, it operates as a subsidiary of Boston Scientific Corporation.